Home Newsfeeds Bloomberg Reported Emerson Set To Bid ~$53/Share for National Instruments

Bloomberg Reported Emerson Set To Bid ~$53/Share for National Instruments

https://www.bloomberg.com/news/articles/2023-01-17/emerson-said-set-to-reveal-7-billion-national-instruments-bid?utm_source=google&utm_medium=bd&cmpId=google&sref=y3YMCJ4e&leadSource=uverify%20wall

byCharles Gross

January 17, 2023

1 minute read

https://www.bloomberg.com/news/articles/2023-01-17/emerson-said-set-to-reveal-7-billion-national-instruments-bid?utm_source=google&utm_medium=bd&cmpId=google&sref=y3YMCJ4e&leadSource=uverify%20wall

Movers
News

What’s Going On With IonQ Inc Stock?

By Erica Kollmann

November 1, 1:10 PM

IonQ, Inc. (NYSE: IONQ) shares are trading higher Wednesday, though the stock remains down by more than 30% over the last month. What To Know:

IONQ

Arm Holdings Analysts Stay Bullish With Licensing Gains Overshadowing Royalty Concerns

By Anusuya Lahiri

November 9, 2:49 PM

BMO Capital analyst Ambrish Srivastava reiterated a Market Perform rating on Arm Holdings Plc (NASDAQ: ARM) with a

ARM

HC Wainwright & Co. Assumes Aprea Therapeutics at Buy, Announces Price Target of $3

By Benzinga Newsdesk

October 10, 6:20 AM

HC Wainwright & Co. analyst Joseph Pantginis assumes Aprea Therapeutics (NASDAQ:APRE) with a Buy rating and announces Price Target of $3.

APRE

Omega Therapeutics Gets FDA Nod For Initial-Stage Liver Cancer Study

By Ragothaman Srinivasan

July 14, 4:55 PM

The U.S. Food and Drug Administration (FDA) has announced clearance to Omega Therapeutics’ (NASDAQ: OMGA) Investigational New Drug (IND) to initiate a Phase 1/2 clinical study of its candidate OTX-2002 for the treatment of hepatocellular carcinoma (HCC).

OMGA

Bloomberg Reported Emerson Set To Bid ~$53/Share for National Instruments

Related Posts

What’s Going On With IonQ Inc Stock?

Arm Holdings Analysts Stay Bullish With Licensing Gains Overshadowing Royalty Concerns

HC Wainwright & Co. Assumes Aprea Therapeutics at Buy, Announces Price Target of $3

Omega Therapeutics Gets FDA Nod For Initial-Stage Liver Cancer Study